Immuno-transcriptomic profiling of extracranial pediatric solid malignancies

颅外儿童实体恶性肿瘤的免疫转录组分析

阅读:1
作者:Andrew S Brohl ,Sivasish Sindiri ,Jun S Wei ,David Milewski ,Hsien-Chao Chou ,Young K Song ,Xinyu Wen ,Jeetendra Kumar ,Hue V Reardon ,Uma S Mudunuri ,Jack R Collins ,Sushma Nagaraj ,Vineela Gangalapudi ,Manoj Tyagi ,Yuelin J Zhu ,Katherine E Masih ,Marielle E Yohe ,Jack F Shern ,Yue Qi ,Udayan Guha ,Daniel Catchpoole ,Rimas J Orentas ,Igor B Kuznetsov ,Nicolas J Llosa ,John A Ligon ,Brian K Turpin ,Daniel G Leino ,Shintaro Iwata ,Irene L Andrulis ,Jay S Wunder ,Silvia R C Toledo ,Paul S Meltzer ,Ching Lau ,Beverly A Teicher ,Heather Magnan ,Marc Ladanyi ,Javed Khan

Abstract

We perform an immunogenomics analysis utilizing whole-transcriptome sequencing of 657 pediatric extracranial solid cancer samples representing 14 diagnoses, and additionally utilize transcriptomes of 131 pediatric cancer cell lines and 147 normal tissue samples for comparison. We describe patterns of infiltrating immune cells, T cell receptor (TCR) clonal expansion, and translationally relevant immune checkpoints. We find that tumor-infiltrating lymphocytes and TCR counts vary widely across cancer types and within each diagnosis, and notably are significantly predictive of survival in osteosarcoma patients. We identify potential cancer-specific immunotherapeutic targets for adoptive cell therapies including cell-surface proteins, tumor germline antigens, and lineage-specific transcription factors. Using an orthogonal immunopeptidomics approach, we find several potential immunotherapeutic targets in osteosarcoma and Ewing sarcoma and validated PRAME as a bona fide multi-pediatric cancer target. Importantly, this work provides a critical framework for immune targeting of extracranial solid tumors using parallel immuno-transcriptomic and -peptidomic approaches.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。